Skip to content
Contact Us
BP Logix · Industry Research

2026 AI in Medical Affairs Industry Benchmark Survey

We asked 79 Medical Affairs professionals across pharmaceutical, biotech, medical communications, and consulting organizations where AI is making it into their workflows, where it isn't, and what's getting in the way.

The confidence–action gap
★ Key Survey Takeaway
Medical Affairs believes in AI. The field isn't acting on that belief yet.
Belief is high
—
are confident AI will improve Medical Affairs efficiency in the next 2–3 years
Action is not
—
describe their organization as “leading edge.” The rest are watching, not leading.
Confidence breakdown
How confident are respondents that AI will improve Medical Affairs efficiency?
What it means

Confidence skews positive but isn't unanimous. 47% are very confident, 39% somewhat confident, and 13% sit in neutral or skeptical territory.

Where the field stands on AI adoption
How organizations describe their current AI adoption posture
What it means

The gap between belief and action is the central tension. Confidence is high, so the slow pace isn't skepticism.

Expected impact areas
Where respondents expect AI to have the most impact
What it means

Time savings and strategic work dominate, while cost reduction trails far behind. This is about bandwidth, not budget.

—
Medical Affairs leadership roles
—
—
Pharma or biotech
—
—
Director-level or above
—
Role breakdown
Primary role
Org type
Organization type
Seniority
Seniority level
Most momentum
Literature monitoring ranks #1 in future interest, and is already tied for #1 implemented.

44% have implemented it; 38% want to expand it further. It's the area generating the most active momentum across the field.

Adoption signals
—
have not implemented any AI use cases yet (watching, but not yet in).
—
have 3 or more use cases live, running multi-use-case deployments already.
What teams have already deployed
Top 5 by current implementation
Where teams want to go next
Top 5 by future interest in the next 12 to 18 months
Use case momentum: implemented vs. future interest
Implemented today (blue) vs. most interested in expanding next 12 to 18 months (teal)
Sort by
Currently implemented
Want to expand (next 12 to 18 mo)
What it means

Teams want more of what they already have. Top future-interest items mirror top current-implementation items. The field wants to expand what's working rather than push into new territory.

Where AI is (and isn't) being deployed
A clear gap separates the two categories: operational and content-focused use cases sit at much higher implementation rates than higher-stakes regulatory ones.
Operational & content work
Avg implementation
—
Regulatory & high-stakes work
Avg implementation
—
What it means

AI is staying out of regulatory work. Operational and content-focused work has been deployed at roughly three times the rate of higher-stakes regulatory work (clinical study reports, health authority engagement, and compliance reporting). The pattern fits the field's caution: where compliance scrutiny is highest, AI deployment is lowest.

The top barrier
—
cite validation and accuracy as their top barrier to AI adoption.
The validation paradox: even as — flag accuracy as the top concern, — still manually review every AI output. AI is being used, but not yet trusted enough to streamline review.
Top barriers to AI adoption
What's actually getting in the way?
What it means

Validation and accuracy tops the list, ahead of compliance. The problem isn't rules; it's trust in the output.

Content validation approaches
How is AI-generated content reviewed before it goes out?
What the data shows

49% use full manual SME review for every AI output.

Only 15% have moved to automated + human hybrid checks.

Blockers by priority use case
Among respondents who flagged each use case as a future priority, what's standing in their way?
About this research

The 2026 AI in Medical Affairs Industry Benchmark Survey collected 79 responses from Medical Affairs professionals between February and May 2026, both online and in person at MAPS Americas 2026 and the ISMPP Annual Meeting. Respondents represent pharmaceutical, biotech, medical communications, CRO, consulting, and other life sciences organizations; 65% are at director level or above. The survey was self-administered and was not designed to be statistically representative of the field as a whole. Results reflect the views of participating respondents.

Conducted by BP Logix. Findings may be cited with attribution to 2026 AI in Medical Affairs Industry Benchmark Survey, BP Logix.

Have questions about the survey results?

Start a conversation today to learn more about integrating AI into mission-critical Medical Affairs workflows.